ѻý

<ѻý class="page-title">Meeting Coverage

SOHO

<ѻý class="page-description">Society of Hematologic Oncology
FLT3 Inhibitor Improves AML Survival With or Without Stem-Cell Transplant

Best outcomes with transplantation, but non-transplant patients also benefited from quizartinib

SOHO over a photo of George R. Brown Convention Center in Houston, Texas.
<ѻý class="section_title">Latest SOHO Meeting Coverage
High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody

Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab

September 11, 2023
Study Questions Value of Interim PET Imaging to Guide Frontline Hodgkin Treatment

One of 40 patients changed treatment but all remained on brentuximab regardless of scan results

September 9, 2023
Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomes

Molecular or cytogenetic response at 3 months correlated with better survival

September 8, 2023
Intensive Pretransplant Consolidation in Older AML Fails to Improve Results

Newer therapies and strategies might show more promise for boosting survival

September 7, 2023
More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adults

Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival

September 7, 2023
Transplant With Orca-T Reduced GVHD in Hematologic Malignancies

Risk of relapse was also lower in the group who received the cell therapy

October 3, 2022
ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma

Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs

October 2, 2022
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma

Belamaf plus lenalidomide-dexamethasone achieved encouraging responses

September 30, 2022
Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?

Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit

September 29, 2022
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS

About a third of patients, including those with TP53 mutations, achieved complete remission

September 29, 2022
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting

Emphasis on novel biological approaches in treating patients with hematologic malignancies

September 26, 2022
Raising the Bar for Myelofibrosis Therapy Development

Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint

September 14, 2020
CML Patients Still Benefit from Transplant

Also at SOHO: Ponatinib proves mettle in pretreated CML

September 13, 2016
Hypomethylating Agents Useful in Low-Risk MDS

Objective responses in a majority of patients

September 8, 2016